{
  "timestamp": "2026-02-11T00:43:30.971Z",
  "endpoint": "https://physician-system-production.up.railway.app/api/mrd-chat",
  "config": {
    "cdsOnly": false,
    "adversarialOnly": false,
    "category": null,
    "limit": 5
  },
  "summary": {
    "totalQuestions": 5,
    "averageScore": 7,
    "passRate": "1/5",
    "passPercentage": 20,
    "passThreshold": 8,
    "maxScore": 10,
    "passing": 1,
    "failing": 4,
    "errors": 0
  },
  "cdsCompliance": {
    "criterion3PassRate": "5/5",
    "criterion4PassRate": "0/5",
    "totalViolations": 9,
    "violations": [
      {
        "questionId": 1,
        "criterion": 4,
        "check": "citation_missing",
        "sentence": "DECISION: Based on the available sources, it is unclear whether adjuvant therapy should be intensified from CAPOX to FOL",
        "reason": "Clinical claim without citation",
        "detail": "\\b(recommend|should|indicated|"
      },
      {
        "questionId": 2,
        "criterion": 4,
        "check": "evidence_levels",
        "detail": "No evidence level characterization found (e.g., randomized, phase III, Category 2A)"
      },
      {
        "questionId": 3,
        "criterion": 4,
        "check": "citation_missing",
        "sentence": "- Evidence: Standard guidelines would not recommend adjuvant therapy for this patient profile (pT4aN0, MSS, no other hig",
        "reason": "Clinical claim without citation",
        "detail": "\\b(recommend|should|indicated|"
      },
      {
        "questionId": 3,
        "criterion": 4,
        "check": "citation_missing",
        "sentence": "- Evidence: Both NCCN and ESMO acknowledge the investigational nature of MRD-guided treatment decisions and recommend cl",
        "reason": "Clinical claim without citation",
        "detail": "\\b(recommend|should|indicated|, \\b(guideline|nccn|asco|esmo)\\b"
      },
      {
        "questionId": 4,
        "criterion": 4,
        "check": "citation_missing",
        "sentence": "- Evidence: Recent validation studies have demonstrated that circulating tumor DNA assays can detect molecular relapse a",
        "reason": "Clinical claim without citation",
        "detail": "\\b(survival|recurrence|respons"
      },
      {
        "questionId": 4,
        "criterion": 4,
        "check": "citation_missing",
        "sentence": "Based on the available sources, it is unclear whether extended therapy carries cumulative toxicity risk without proven s",
        "reason": "Clinical claim without citation",
        "detail": "\\b(treatment|therapy|regimen|p"
      },
      {
        "questionId": 5,
        "criterion": 4,
        "check": "citation_missing",
        "sentence": "- Evidence: Recent prospective data suggest substantial lead time over imaging-based detection, with breast cancer studi",
        "reason": "Clinical claim without citation",
        "detail": "\\b(recommend|should|indicated|, \\b(survival|recurrence|respons"
      },
      {
        "questionId": 5,
        "criterion": 4,
        "check": "citation_missing",
        "sentence": "Serial monitoring can help distinguish true molecular relapse from assay noise, and recent data suggest that longitudina",
        "reason": "Clinical claim without citation",
        "detail": "\\b(recommend|should|indicated|, \\b(survival|recurrence|respons"
      },
      {
        "questionId": 5,
        "criterion": 4,
        "check": "citation_missing",
        "sentence": "Based on the available sources, it is unclear whether there is an established threshold for tumor fraction or variant al",
        "reason": "Clinical claim without citation",
        "detail": "\\b(recommend|should|indicated|"
      }
    ]
  },
  "categoryAverages": {
    "clinical_scenario": 7
  },
  "dimensionAverages": {
    "accuracy": 1,
    "completeness": 1.2,
    "evidence_quality": 1,
    "automation_bias_mitigation": 1,
    "criterion3_nondirective": 2,
    "criterion4_transparency": 0.8
  },
  "results": [
    {
      "id": 1,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "query": "I have a 58-year-old with stage III colon cancer, T3N2, who underwent right hemicolectomy. Signatera came back MRD-positive at the 4-week post-op timepoint. Already planning CAPOX â€” should I be thinking about intensifying to FOLFOXIRI based on the MRD status?",
      "total": 8,
      "pass": true,
      "automated": {
        "criterion3": 2,
        "criterion4": 1,
        "subtotal": 3
      },
      "llm": {
        "accuracy": 1,
        "completeness": 2,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 5
      },
      "cdsViolations": 1,
      "mustMentionMissing": [],
      "llmSummary": "LLM score 5/7 (extracted from malformed JSON)",
      "error": null
    },
    {
      "id": 2,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "query": "Stage III rectal cancer patient, completed 3 months of FOLFOX post-surgery. Signatera just came back MRD-negative. Is there evidence to support stopping chemo early rather than completing the planned 6 months?",
      "total": 6,
      "pass": false,
      "automated": {
        "criterion3": 2,
        "criterion4": 0,
        "subtotal": 2
      },
      "llm": {
        "accuracy": 1,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 4
      },
      "cdsViolations": 1,
      "mustMentionMissing": [],
      "llmSummary": "LLM score 4/7 (extracted from malformed JSON)",
      "error": null
    },
    {
      "id": 3,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "query": "64-year-old, stage II colon cancer, pT4aN0, MSS, no high-risk features besides T4a. Post-surgery Signatera is MRD-positive. Standard guidelines wouldn't call for adjuvant chemo here. What does the MRD data say about treating these patients?",
      "total": 7,
      "pass": false,
      "automated": {
        "criterion3": 2,
        "criterion4": 1,
        "subtotal": 3
      },
      "llm": {
        "accuracy": 1,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 4
      },
      "cdsViolations": 2,
      "mustMentionMissing": [],
      "llmSummary": "LLM score 4/7 (extracted from malformed JSON)",
      "error": null
    },
    {
      "id": 4,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "query": "TNBC patient, had neoadjuvant AC-T, partial response, then surgery with residual disease. Post-op Signatera is MRD-positive. She already got capecitabine per CREATE-X. Any ctDNA-guided options beyond that?",
      "total": 7,
      "pass": false,
      "automated": {
        "criterion3": 2,
        "criterion4": 1,
        "subtotal": 3
      },
      "llm": {
        "accuracy": 1,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 4
      },
      "cdsViolations": 2,
      "mustMentionMissing": [],
      "llmSummary": "LLM score 4/7 (extracted from malformed JSON)",
      "error": null
    },
    {
      "id": 5,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "query": "HR+/HER2- breast cancer, stage IIA, had lumpectomy + adjuvant ET. Now 18 months out, surveillance Signatera just turned positive. No imaging findings yet. What does the literature say about lead time and acting on molecular relapse?",
      "total": 7,
      "pass": false,
      "automated": {
        "criterion3": 2,
        "criterion4": 1,
        "subtotal": 3
      },
      "llm": {
        "accuracy": 1,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 4
      },
      "cdsViolations": 3,
      "mustMentionMissing": [],
      "llmSummary": "LLM score 4/7 (extracted from malformed JSON)",
      "error": null
    }
  ]
}